Latest News

Nationwide distribution agreement with Occlutech

April 17th, 2024

RSK Medical is pleased to announce a new nationwide distribution agreement with Occlutech (Sweden), a leading specialist of minimally invasive cardiac devices effective May 1st, 2024.  Occlutech has developed, manufactured and commercialized minimally invasive implants for over 20 years.  They offer a broad and proven portfolio designed to address Congenital Heart Disease, Stroke Prevention & Adult Intervention and Heart Failure with PFO, ASD and VSD devices.

Read more: Occlutech website

First Use of ANGIODROID Automated Carbon Dioxide Angiography Injector

February 7th, 2024

RSK Medical Inc. is pleased to announce the completion of the first 8 ANGIODROID CO2 Injector cases in Canada in Interventional Radiology at the Centre hospalitalier de l’Université de Montreal (CHUM) last week under the Health Canada Special Access program. A variety of patients received venous or arterial CO2 angiograms due to restrictions related to the use of contrast media.

Thank you to Drs. Bouchard, Therasse, Perrault, Amaral and the Radiology hospital administration and their full clinical team for their great support.

CO2 angiography is an effective alternative to iodine without the risk of further impairment of renal function providing excellent imaging, improved safety and saves costs by using less iodine accompanied by fewer related complications.

VENUS-MEDTECH Venus-P Approved by Health Canada

January 30th, 2024

RSK Medical, distributors of the VENUS-MEDTECH’s Venus-P transcatheter pulmonary valve and delivery system is proud to announce the recent Class IV approval by Health Canada. Venus-P is a self-expanding multi-level support frame with a tri-leaflet pericardium tissue valve. The Venus-P represents a significant new offering for patients suitable for a transcatheter procedure. The valve itself is available in 5 different diameters in 25 mm and 30 mm lengths far exceeding the offerings of alternative suppliers.

“Pocket Press” for Cardiac Implantable Electronic Devices

August 10th, 2023

RSK Medical has begun distribution of the “Pocket Press” for Cardiac Implantable Electronic Devices (CIED*) across Canada. This new modern pressure bandage is manufactured by Compress Innovations after significant experience in the wound and implantable cardiac rhythm devices industry. With significant CRM experience in the industry, we look forward to standardizing and improving the pressure dressing over devices to reduce the incidence of hematomas in this large group of patients.

The Pocket Press is pre-assembled with a standardized level of compression utilizing a 3-anchor design and a high density foam to maximize compression over the pocket. Please view the Virtual In-service video at the website: www.pressuredressings.com. We are pleased to provide a means of reducing the number of hematomas and therefore the further risk of infections in device patients.

TricValve® – Transcatheter Bicaval Valves System

April 13, 2023

We are very pleased to announce a distribution agreement across Canada for the P&F TRICVALVE TRANSCATHETER BICAVAL VALVES system. It is designed for the treatment of severe and symptomatic Tricuspid Regurgitation. The system consists of two self-expanding valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux. The bioprostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. It is especially intended for use for patients who are not candidates for open surgical therapy.

The system does not yet have regulatory approval in Canada. The TRICVALVE system is approved for use in Europe (CE Mark) with now over 1,000 implants worldwide.

Pulmonary Valve Replacement-VENUS-MEDTECH agreement

November 7th, 2022

RSK Medical Inc. is pleased to announce a distribution agreement with VENUS-MEDTECH, a leader in transcatheter structural heart valve therapies in Asia and Europe.  RSK Medical is distributing the VENUS-P Valve system which is the first self-expanding nitinol stent designed specifically for pulmonary valve replacement.
The purpose of the VENUS-P is to replace the native or repaired  pulmonary heart valve with an artificial (biological) valve using a minimally invasive approach to treat RVOT dysfunction to restore proper pulmonary valve function.
To date, VENUS-P Valve implants have been completed at St. Paul’s Hospital, Toronto General Hospital and the Montreal Heart Institute under the special access process via Health Canada.

RSK Medical Inc. is pleased to announce a nationwide distribution agreement with Texray AB

April 28th, 2022

RSK Medical Inc. is pleased to announce a nationwide distribution agreement with Texray AB located in Kungsbacka, Sweden effective immediately.

Texray has invented the only radiation protection textile in the world.  Their unique material and product design can reduce scatter radiation towards the head and neck by up to 97% to enhance the safety of healthcare professionals.

The Texray product line can be used in interventional electrophysiology, cardiology, radiology and endovascular surgery procedures where RSK Medical already offers other specialty products.

We look forward to introducing the Texray radiation protection products across Canada.

Read more at the Texray web site.

New Distribution Agreement with Angiodroid, manufacturer of the CO2 Injector

March 24, 2021

RSK Medical Inc. has signed a long term agreement (Canada-wide) to represent Angiodroid Srl from Bologna, Italy.

Angiodroid manufacturers The CO2 Injector, the first system for Automated Carbon Dioxide Angiography (ACDA) dedicated to diagnostic and interventional procedures in peripheral and venous systems.

The Safety and Efficacy of Angiodroid’s CO2 injector has been validated in over 20 international clinical studies to date. This technology makes it possible to use CO2, a 100% biocompatible gas to obtain high quality radiological angiographic images while preserving the renal function of the patients. The ACDA system system avoids all contrast induced nephropathy risks and potential for allergic reactions.

Angiodroid has begun preparation for submitting for Health Canada regulatory approval. Find more on www.angiodroid.com.

Prytime Medical Health Canada approval for New ER-REBOA PLUS Catheter

November 17, 2020

Prytime Medical Devices, Inc. introduced its latest aortic occlusion catheter. The ER-REBOA PLUS catheter is designed for improved ease of use, now guide wire-compatible (up to .025 “) with improved depth markings for insertion without imaging.

“The original ER-REBOATM catheter was an important start in delivering a new technology to help clinicians stabilize and manage certain scenarios of bleeding and shock; a technology that, to date, has contributed to saving hundreds of lives,” said Col. (Dr.) Todd Rasmussen, Director of the Battlefield Shock and Resuscitation Research Program at the Uniformed Services University of the Health Sciences. “However, we recognized from the outset that the original design and device would evolve. Even iterative changes in the technology, such as with the ER-REBOATM PLUS, stand to make the devices easier to use, safer and more effective.“

Distribution agreement with NeoChord Inc.

September 08, 2020

RSK Medical Inc. is pleased to announce the signing of a distribution agreement with NeoChord Inc., a privately held medical technology company leading the advancement of mitral valve repair (MVR) in patients suffering from mitral regurgitation.  The NeoChord procedure is a beating heart, echo-guided treatment option for patients with MVR and is proven to resolve and restore normal mitral valve function.  The technology allows for a minimally invasive procedure for moderate to severe degenerative disease while the heart is beating and without the need for cardio-pulmonary bypass or aortic cross-clamping.

COVID-19 Statement

May 02, 2020

RSK Medical Inc. and its many suppliers would like to thank all the medical care providers and essential workers for their heroic efforts during the current COVID-10 pandemic.  The great commitment and continued support will not be forgotten.